| Trial ID: | L2030 |
| Source ID: | NCT03178591
|
| Associated Drug: |
Vildagliptin
|
| Title: |
Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2|Ischemic Heart Disease
|
| Interventions: |
DRUG: vildagliptin|DRUG: Dapagliflozin
|
| Outcome Measures: |
Primary: Number of participants who has ST segment depression in ambulatory ECG monitoring during 24 hours at 6 months between DPP4 inhibitor (vildaglptin) group and SGLT2 inhibitors (Dapagliflozin) group, 6 months|Number of myocardial dysfunction which verified by Exercise stress test at 6 month between DPP4 inhibitor (vildaglptin) group and SGLT2 inhibitors (Dapagliflozin) group, 6 months|The event of autonomic dysfunction from heart rate variability, heart rate turbulence, QT interval at 6 month between DPP4 inhibitor (vildaglptin) group and SGLT2 inhibitors (Dapagliflozin) group, 6 months|The myocardial injury event which verified by hsTnT level at 6 month between DPP4 inhibitor (vildaglptin) group and SGLT2 inhibitors (Dapagliflozin) group, 6 months|The inflammation event which verified by hsCRP, IL-6 and TNF-alpha level at 6 month between DPP4 inhibitor (vildaglptin) group and SGLT2 inhibitors (Dapagliflozin) group, 6 months|The oxidative stress event which verified by MDA and 8-isoprostaglandin F2 alpha level at 6 month between DPP4 inhibitor (vildaglptin) group and SGLT2 inhibitors (Dapagliflozin) group, 6 months|The ventricular wall stretch event which verified by N-terminal ProBNP level between DPP4 inhibitor (vildaglptin) group and SGLT2 inhibitors (Dapagliflozin) group., 6 months|The average of systolic blood pressure at 6 month between DPP4 inhibitor (vildaglptin) group and SGLT2 inhibitors (Dapagliflozin) group., 6 months |
|
| Sponsor/Collaborators: |
Sponsor: Chiang Mai University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
43
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2014-10
|
| Completion Date: |
2018-07
|
| Results First Posted: |
|
| Last Update Posted: |
2018-07-19
|
| Locations: |
Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand
|
| URL: |
https://clinicaltrials.gov/show/NCT03178591
|
